Trial Profile

An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; VXM-01 (Primary) ; Ascorbic acid; Lactose; Sodium bicarbonate
Indications Glioblastoma
Focus Adverse reactions
Sponsors VAXIMM

Most Recent Events

03 Aug 2026 According to OSR Health Media Release, the Company intends to submit these findings to a peer-reviewed scientific journal and is expected to announce further top-line results soon
03 Aug 2026 Results presented in the OSR Health Media Release
26 Mar 2025 Status changed from active, no longer recruiting to completed as per Vaximm AG media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com